vonafexor + nucleotide analogue

**vonafexor + nucleotide analogue** is a combination regimen under clinical investigation for the treatment of chronic hepatitis B virus (HBV) infection and potentially other indications. The combination typically consists of **vonafexor** (also known as EYP001a), a potent oral Farnesoid X Receptor (FXR) agonist, together with a **nucleotide analogue antiviral** such as entecavir or tenofovir disoproxil. - **Vonafexor** modulates the FXR nuclear receptor, affecting bile acid metabolism and viral gene regulation, thus inhibiting HBV replication and modulating metabolic pathways. - **Nucleotide analogues** inhibit viral DNA polymerase, leading to chain termination during viral replication. - The combination aims to enhance antiviral efficacy by simultaneously targeting both the viral replication machinery (with the nucleotide analogue) and host metabolism/viral cccDNA (via FXR agonism). - Developed primarily by ENYO Pharma, this combination has been investigated in Phase 2 studies as "EYP001a + nucleotide analogue" and typically uses entecavir or tenofovir disoproxil as the nucleotide analogue component. - Notably, trials have included combinations such as "vonafexor + entecavir" and "vonafexor + tenofovir disoproxil," with regimens aiming to increase rates of functional HBV cure.